Expertise in
27
conditions

Dr. Stephen H. Caldwell

Gastroenterology
UVA Health Digestive Health Center
1215 Lee St, 
Charlottesville, VA 
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
UVA Health Digestive Health Center
1215 Lee St, 
Charlottesville, VA 

Overview

Stephen Caldwell is a Gastroenterologist practicing medicine in Charlottesville, Virginia.

Dr. Caldwell is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Endoscopy.

He is actively involved in clinical research, co-authoring 149 peer reviewed articles and participating in 8 clinical trials. Dr. Caldwell is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in VA

Hospital Affiliations

University Of Virginia Medical Center
Augusta Health

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UVA Health Digestive Health Center
1215 Lee St, Charlottesville, VA 22908

Additional Areas of Focus

Dr. Caldwell has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Enrollment Status: Completed
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drug: CNP-104
Study Phase: Phase 1/Phase 2
Defining the Mechanisms Underlying Adrenal Dysfunction in Cirrhosis and Its Prognostic Significance
Defining the Mechanisms Underlying Adrenal Dysfunction in Cirrhosis and Its Prognostic Significance
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Drug
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study
Enrollment Status: Terminated
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Not Applicable
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
Enrollment Status: Terminated
Publish Date: January 25, 2019
Intervention Type: Biological, Other
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

149 Total Publications

A Changing Paradigm: The Swift Expansion of Adult Living Donor Liver Transplantation for MASH Cirrhosis.
A Changing Paradigm: The Swift Expansion of Adult Living Donor Liver Transplantation for MASH Cirrhosis.
Journal: Research square
Published: September 03, 2026
Similar Doctors
Expertise in
30
conditions
Dr. Andrew Y. Wang
Gastroenterology
Expertise in
30
conditions
Dr. Andrew Y. Wang
Gastroenterology
Referral may be required

UVA Health Digestive Health Center

1215 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-243-3090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Wang is a Gastroenterologist practicing medicine in Charlottesville, Virginia. Dr. Wang is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Achalasia, Chronic Pancreatitis, Hereditary Pancreatitis, Endoscopy, and Gastrectomy. Dr. Wang is currently accepting new patients.

Expertise in
22
conditions
Dr. Nicolas M. Intagliata
Gastroenterology
Expertise in
22
conditions
Dr. Nicolas M. Intagliata
Gastroenterology
Referral may be required

UVA Health Digestive Health Center

1215 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-243-3090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicolas Intagliata is a Gastroenterologist practicing medicine in Charlottesville, Virginia. Dr. Intagliata is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Liver Failure, Cirrhosis, Spontaneous Bacterial Peritonitis, Liver Transplant, and Endoscopy. Dr. Intagliata is currently accepting new patients.

Expertise in
25
conditions
Dr. Daniel S. Strand
Gastroenterology
Expertise in
25
conditions
Dr. Daniel S. Strand
Gastroenterology
Referral may be required

UVA Health Digestive Health At Primary Care Center

1221 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-243-3090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Strand is a Gastroenterologist practicing medicine in Charlottesville, Virginia. Dr. Strand is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Chronic Pancreatitis, Bile Duct Obstruction, Bile Duct Stricture, Endoscopy, and Pancreatectomy. Dr. Strand is currently accepting new patients.

Frequently Asked Questions about Dr. Stephen H. Caldwell

How do I make an appointment with Dr. Stephen H. Caldwell?

You can book an appointment with Dr. Stephen H. Caldwell by calling their office at 434-243-3090. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen H. Caldwell a top-rated expert for Nonalcoholic Steatohepatitis (NASH)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen H. Caldwell is classified as an Elite expert for Nonalcoholic Steatohepatitis (NASH), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen H. Caldwell specialize in?

While Dr. Stephen H. Caldwell is a Gastroenterology, they have specific expertise in Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Stephen H. Caldwell participate in research or clinical trials?

Yes. Dr. Stephen H. Caldwell has published 149 articles and abstracts on conditions like Nonalcoholic Steatohepatitis (NASH). You can view a list of Dr. Stephen H. Caldwell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephen H. Caldwell accept my insurance?

Dr. Stephen H. Caldwell accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 434-243-3090 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Caldwell's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 12 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile